36531241|t|Host genetics impact on SARS-CoV-2 vaccine-induced immunoglobulin levels and dynamics: The role of TP53, ABO, APOE, ACE2, HLA-A, and CRP genes.
36531241|a|Background: Development and worldwide availability of safe and effective vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) to fight severe symptoms of coronavirus disease 2019 (COVID-19) and block the pandemic have been a great achievement and stimulated researchers on understanding the efficacy and duration of different vaccine types. Methods: We investigated the levels of anti-SARS-CoV-2 antibodies (IgG) and neutralizing antibodies (NAbs) in 195 healthy adult subjects belonging to the staff of the University-Hospital of Ferrara (Italy) starting from 15 days up to 190 days (about 6 months) after the second dose of the BNT162b2 (Pfizer-BioNTech) mRNA-based vaccine (n = 128) or ChAdOx1 (AstraZeneca) adenovirus-based vaccine (n = 67) using a combined approach of serological and genomics investigations. Results: A strong correlation between IgG and NAb levels was detected during the 190 days of follow-up (r 2 = 0.807; p < 0.0001) and was confirmed during the first 90 days (T1) after vaccination (r 2 = 0.789; p = 0.0001) and 91-190 days (T2) after vaccination (r 2 = 0.764; p = 0.0001) for both vaccine types (r 2 = 0.842; p = 0.0001 and r 2 = 0.780; p = 0.0001 for mRNA- and adenovirus-based vaccine, respectively). In addition to age (p < 0.01), sex (p = 0.03), and type of vaccine (p < 0.0001), which partially accounted for the remarkable individual differences observed in the antibody levels and dynamics, interesting genetic determinants appeared as significant modifiers of both IgG and NAb responses among the selected genes investigated (TP53, rs1042522; APOE, rs7412/rs429358; ABO, rs657152; ACE2, rs2285666; HLA-A rs2571381/rs2499; CRP, rs2808635/rs876538; LZTFL1, rs35044562; OAS3, rs10735079; SLC6A20, rs11385942; CFH, rs1061170; and ACE1, ins/del, rs4646994). In detail, regression analysis and mean antibody level comparison yielded appreciable differences after genotype stratification (P1 and P2, respectively, for IgG and NAb distribution) in the whole cohort and/or in the mRNA-based vaccine in the following genes: TP53, rs1042522 (P1 = 0.03; P2 = 0.04); ABO, rs657152 (P1 = 0.01; P2 = 0.03); APOE, rs7412/rs429358 (P1 = 0.0018; P2 = 0.0002); ACE2, rs2285666 (P1 = 0.014; P2 = 0.009); HLA-A, rs2571381/rs2499 (P1 = 0.02; P2 = 0.03); and CRP, rs2808635/rs876538 (P1 = 0.01 and P2 = 0.09). Conclusion: High- or low-responsive subjects can be identified among healthy adult vaccinated subjects after targeted genetic screening. This suggests that favorable genetic backgrounds may support the progression of an effective vaccine-induced immune response, though no definite conclusions can be drawn on the real effectiveness ascribed to a specific vaccine or to the different extent of a genotype-driven humoral response. The interplay between data from the polygenic predictive markers and serological screening stratified by demogeographic information can help to recognize the individual humoral response, accounting for ethnic and geographical differences, in both COVID-19 and anti-SARS-CoV-2 vaccinations.
36531241	24	34	SARS-CoV-2	Species	2697049
36531241	99	103	TP53	Gene	7157
36531241	105	108	ABO	Gene	28
36531241	110	114	APOE	Gene	348
36531241	116	120	ACE2	Gene	59272
36531241	122	127	HLA-A	Gene	3105
36531241	133	136	CRP	Gene	1401
36531241	234	281	severe acute respiratory syndrome coronavirus-2	Species	2697049
36531241	283	293	SARS-CoV-2	Species	2697049
36531241	304	347	severe symptoms of coronavirus disease 2019	Disease	MESH:D000086382
36531241	349	357	COVID-19	Disease	MESH:D000086382
36531241	554	564	SARS-CoV-2	Species	2697049
36531241	880	890	adenovirus	Species	10508
36531241	1030	1033	NAb	Gene	
36531241	1360	1370	adenovirus	Species	10508
36531241	1679	1682	NAb	Gene	
36531241	1732	1736	TP53	Gene	7157
36531241	1738	1747	rs1042522	SNP	tmVar:rs1042522;VariantGroup:11;CorrespondingGene:7157;RS#:1042522;CorrespondingSpecies:9606
36531241	1749	1753	APOE	Gene	348
36531241	1755	1761	rs7412	SNP	tmVar:rs7412;VariantGroup:13;CorrespondingGene:348;RS#:7412;CorrespondingSpecies:9606
36531241	1762	1770	rs429358	SNP	tmVar:rs429358;VariantGroup:12;CorrespondingGene:348;RS#:429358;CorrespondingSpecies:9606
36531241	1772	1775	ABO	Gene	28
36531241	1777	1785	rs657152	SNP	tmVar:rs657152;VariantGroup:3;CorrespondingGene:28;RS#:657152;CorrespondingSpecies:9606
36531241	1787	1791	ACE2	Gene	59272
36531241	1793	1802	rs2285666	SNP	tmVar:rs2285666;VariantGroup:4;CorrespondingGene:59272;RS#:2285666;CorrespondingSpecies:9606
36531241	1804	1809	HLA-A	Gene	3105
36531241	1810	1819	rs2571381	SNP	tmVar:rs2571381;VariantGroup:10;CorrespondingGene:3105;RS#:2571381;CorrespondingSpecies:9606
36531241	1820	1826	rs2499	SNP	tmVar:rs2499;VariantGroup:1;CorrespondingGene:3105;RS#:2499;CorrespondingSpecies:9606
36531241	1828	1831	CRP	Gene	1401
36531241	1833	1842	rs2808635	SNP	tmVar:rs2808635;VariantGroup:8;RS#:2808635
36531241	1843	1851	rs876538	SNP	tmVar:rs876538;VariantGroup:2;RS#:876538
36531241	1853	1859	LZTFL1	Gene	54585
36531241	1861	1871	rs35044562	SNP	tmVar:rs35044562;VariantGroup:5;CorrespondingGene:54585;RS#:35044562;CorrespondingSpecies:9606
36531241	1873	1877	OAS3	Gene	4940
36531241	1879	1889	rs10735079	SNP	tmVar:rs10735079;VariantGroup:0;CorrespondingGene:4940;RS#:10735079;CorrespondingSpecies:9606
36531241	1891	1898	SLC6A20	Gene	54716
36531241	1900	1910	rs11385942	SNP	tmVar:rs11385942;VariantGroup:6;CorrespondingGene:54585;RS#:11385942;CorrespondingSpecies:9606
36531241	1912	1915	CFH	Gene	3075
36531241	1917	1926	rs1061170	SNP	tmVar:rs1061170;VariantGroup:9;CorrespondingGene:3075;RS#:1061170;CorrespondingSpecies:9606
36531241	1932	1936	ACE1	Gene	1636
36531241	1947	1956	rs4646994	SNP	tmVar:rs4646994;VariantGroup:7;CorrespondingGene:1636;RS#:4646994;CorrespondingSpecies:9606
36531241	2125	2128	NAb	Gene	
36531241	2220	2224	TP53	Gene	7157
36531241	2226	2235	rs1042522	SNP	tmVar:rs1042522;VariantGroup:11;CorrespondingGene:7157;RS#:1042522;CorrespondingSpecies:9606
36531241	2260	2263	ABO	Gene	28
36531241	2265	2273	rs657152	SNP	tmVar:rs657152;VariantGroup:3;CorrespondingGene:28;RS#:657152;CorrespondingSpecies:9606
36531241	2298	2302	APOE	Gene	348
36531241	2304	2310	rs7412	SNP	tmVar:rs7412;VariantGroup:13;CorrespondingGene:348;RS#:7412;CorrespondingSpecies:9606
36531241	2311	2319	rs429358	SNP	tmVar:rs429358;VariantGroup:12;CorrespondingGene:348;RS#:429358;CorrespondingSpecies:9606
36531241	2348	2352	ACE2	Gene	59272
36531241	2354	2363	rs2285666	SNP	tmVar:rs2285666;VariantGroup:4;CorrespondingGene:59272;RS#:2285666;CorrespondingSpecies:9606
36531241	2390	2395	HLA-A	Gene	3105
36531241	2397	2406	rs2571381	SNP	tmVar:rs2571381;VariantGroup:10;CorrespondingGene:3105;RS#:2571381;CorrespondingSpecies:9606
36531241	2407	2413	rs2499	SNP	tmVar:rs2499;VariantGroup:1;CorrespondingGene:3105;RS#:2499;CorrespondingSpecies:9606
36531241	2442	2445	CRP	Gene	1401
36531241	2447	2456	rs2808635	SNP	tmVar:rs2808635;VariantGroup:8;RS#:2808635
36531241	2457	2465	rs876538	SNP	tmVar:rs876538;VariantGroup:2;RS#:876538
36531241	3170	3178	COVID-19	Disease	MESH:D000086382
36531241	3188	3198	SARS-CoV-2	Species	2697049
36531241	Association	RS#:10735079;CorrespondingGene:4940	RS#:35044562;CorrespondingGene:54585
36531241	Association	RS#:1061170;CorrespondingGene:3075	RS#:35044562;CorrespondingGene:54585
36531241	Association	RS#:10735079;CorrespondingGene:4940	RS#:4646994;CorrespondingGene:1636
36531241	Association	RS#:11385942;CorrespondingGene:54585	RS#:35044562;CorrespondingGene:54585
36531241	Association	RS#:10735079;CorrespondingGene:4940	RS#:11385942;CorrespondingGene:54585
36531241	Association	4940	54716
36531241	Association	RS#:35044562;CorrespondingGene:54585	RS#:4646994;CorrespondingGene:1636
36531241	Association	1636	3075
36531241	Association	1636	54716
36531241	Association	1636	4940
36531241	Association	3075	54716
36531241	Association	3075	4940

